EP 3603677 A1 20200205 - MODULATORS OF COMPLEMENT FACTOR B

Title (en)

MODULATORS OF COMPLEMENT FACTOR B

Title (de)

INHIBITOREN DES KOMPLEMENTFAKTORS B

Title (fr)

MODULATEURS DU FACTEUR B DU COMPLÉMENT

Publication

EP 3603677 A1 20200205 (EN)

Application

EP 19182415 A 20140912

Priority

US 201361877624 P 20130913
EP 14844168 A 20140912
US 2014055458 W 20140912

Abstract (en)

The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.

IPC 8 full level

A61K 48/00 (2006.01); C12N 15/113 (2010.01)

CPC (source: EA EP RU US)

A61P 13/00 (2018.01 - EA EP); A61P 13/12 (2018.01 - EA EP); A61P 27/02 (2018.01 - EA EP); A61P 43/00 (2018.01 - EA EP); C12N 15/1137 (2013.01 - EA EP RU US); C12Y 304/21047 (2013.01 - EA EP RU US); C12N 2310/11 (2013.01 - EA EP US); C12N 2310/315 (2013.01 - EA US); C12N 2310/321 (2013.01 - EA US); C12N 2310/3231 (2013.01 - EA US); C12N 2310/3341 (2013.01 - EA US)

Citation (applicant)

WO 2011139702 A2 20111110 - ISIS PHARMACEUTICALS INC [US], et al
WO 0063364 A2 20001026 - AMERICAN HOME PROD [US], et al
US 6673661 B1 20040106 - LIU CHI-WEN [TW], et al
US 0333466 W 20031020
WO 2008101157 A1 20080821 - ISIS PHARMACEUTICALS INC [US], et al
US 2005130923 A1 20050616 - BHAT BALKRISHEN [US], et al
WO 2007134181 A2 20071122 - ISIS PHARMACEUTICALS INC [US], et al
US 7399845 B2 20080715 - SETH PUNIT P [US], et al
WO 2009006478 A2 20090108 - ISIS PHARMACEUTICALS INC [US], et al
WO 2008150729 A2 20081211 - ISIS PHARMACEUTICALS INC [US], et al
US 2004171570 A1 20040902 - ALLERSON CHARLES [US], et al
US 7427672 B2 20080923 - IMANISHI TAKESHI [JP], et al
WO 2008154401 A2 20081218 - ISIS PHARMACEUTICALS INC [US], et al
US 6268490 B1 20010731 - IMANISHI TAKESHI [JP], et al
US 6525191 B1 20030225 - RAMASAMY KANDA S [US]
US 6670461 B1 20031230 - WENGEL JESPER [DK], et al
US 6770748 B2 20040803 - IMANISHI TAKESHI [JP], et al
US 6794499 B2 20040921 - WENGEL JESPER [DK], et al
US 7034133 B2 20060425 - WENGEL JESPER [DK], et al
US 7053207 B2 20060530 - WENGEL JESPER [DK]
US 7547684 B2 20090616 - SETH PUNIT P [US], et al
US 7696345 B2 20100413 - ALLERSON CHARLES [US], et al
US 2008039618 A1 20080214 - ALLERSON CHARLES [US], et al
US 2009012281 A1 20090108 - SWAYZE ERIC E [US], et al
WO 9414226 A1 19940623 - HONEYWELL INC [US]
DK 9800393 W 19980914
WO 9914226 A2 19990325 - EXIQON A S [DK], et al
WO 9839352 A1 19980911 - IMANISHI TAKESHI [JP], et al
US 5698685 A 19971216 - SUMMERTON JAMES E [US], et al
US 5166315 A 19921124 - SUMMERTON JAMES E [US], et al
US 5185444 A 19930209 - SUMMERTON JAMES E [US], et al
US 5034506 A 19910723 - SUMMERTON JAMES E [US], et al
WO 2010036696 A1 20100401 - ISIS PHARMACEUTICALS INC [US], et al
WO 2006047842 A2 20060511 - LEUVEN K U RES & DEV [BE], et al
WO 0149687 A2 20010712 - LEUVEN K U RES & DEV [BE], et al
US 4981957 A 19910101 - LEBLEU BERNARD [FR], et al
US 5118800 A 19920602 - SMITH LLOYD M [US], et al
US 5319080 A 19940607 - LEUMANN CHRISTIAN [CH]
US 5359044 A 19941025 - COOK PHILLIP D [US], et al
US 5393878 A 19950228 - LEUMANN CHRISTIAN [CH]
US 5446137 A 19950829 - MAAG HANS [US], et al
US 5466786 A 19951114 - BUHR CHRIS A [US], et al
US 5514785 A 19960507 - VAN NESS JEFFREY [US], et al
US 5519134 A 19960521 - ACEVEDO OSCAR L [US], et al
US 5567811 A 19961022 - MISIURA KONRAD [PL], et al
US 5576427 A 19961119 - COOK PHILIP D [US], et al
US 5591722 A 19970107 - MONTGOMERY JOHN A [US], et al
US 5597909 A 19970128 - URDEA MICHAEL S [US], et al
US 5610300 A 19970311 - ALTMANN KARL-HEINZ [CH], et al
US 5627053 A 19970506 - USMAN NASSIM [US], et al
US 5639873 A 19970617 - BARASCUT JEAN-LOUIS [FR], et al
US 5646265 A 19970708 - MCGEE DANIEL PETER CLAUDE [US]
US 5670633 A 19970923 - COOK PHILLIP DAN [US], et al
US 5700920 A 19971223 - ALTMANN KARL-HEINZ [CH], et al
US 5792847 A 19980811 - BUHR CHRIS A [US], et al
US 6600032 B1 20030729 - MANOHARAN MUTHIAH [US], et al
US 2005019219 W 20050602
WO 2005121371 A2 20051222 - ISIS PHARMACEUTICALS INC [US], et al
WO 03004602 A2 20030116 - ISIS PHARMACEUTICALS INC [US], et al
"GENBANK", Database accession no. XM -001113553.2
WOOLF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 7305 - 7309
GAUTSCHI ET AL., J. NATL. CANCER INST, vol. 93, March 2001 (2001-03-01), pages 463 - 471
MAHERDOLNICK, NUC. ACID. RES., vol. 16, 1988, pages 3341 - 3358
PAL-BHADRA ET AL., SCIENCE, vol. 303, 2004, pages 669 - 672
VOLPE ET AL., SCIENCE, vol. 297, 2002, pages 2232 - 2237
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ZHANGMADDEN, GENOME RES., vol. 7, 1997, pages 649 656
SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482 489
CHATTOPADHYAYA ET AL., J. ORG. CHEM., vol. 74, 2009, pages 118 - 134
SINGH ET AL., CHEM. COMMUN., vol. 4, 1998, pages 455 - 456
KOSHKIN ET AL., TETRAHEDRON, vol. 54, 1998, pages 3607 - 3630
WAHLESTEDT ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 97, 2000, pages 5633 - 5638
KUMAR ET AL., BIOORG. MED. CHEM. LETT., vol. 8, 1998, pages 2219 - 2222
SINGH ET AL., J. ORG. CHEM., vol. 63, 1998, pages 10035 - 10039
NAUWELAERTS ET AL., J. AM. CHEM. SOC., vol. 129, no. 30, 2007, pages 9340 - 9348
ELAYADI ET AL., CURR. OPINION INVEST. DRUGS, vol. 2, 2001, pages 558 - 561
BRAASCH ET AL., CHEM. BIOL., vol. 8, 2001, pages 1 - 7
ORUM ET AL., CURR. OPINION MOL. THER., vol. 3, 2001, pages 239 - 243
FRIEDEN ET AL., NUCLEIC ACIDS RESEARCH, vol. 21, 2003, pages 6365 - 6372
FREIER ET AL., NUCLEIC ACIDS RESEARCH, vol. 25, no. 22, 1997, pages 4429 - 4443
ALBAEK ET AL., J. ORG. CHEM., vol. 71, 2006, pages 7731 - 7740
BAKER ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 11944 - 12000
MARTIN, HELV. CHIM. ACTA, vol. 78, 1995, pages 486 - 504
ALTMANN ET AL., CHIMIA, vol. 50, 1996, pages 168 - 176
ALTMANN ET AL., BIOCHEM. SOC. TRANS., vol. 24, 1996, pages 630 - 637
ALTMANN ET AL., NUCLEOSIDES NUCLEOTIDES, vol. 16, 1997, pages 917 - 926
LEUMANN, BIOORG. MED. CHEM., vol. 10, 2002, pages 841 - 854
BRAASCH ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 4503 - 4510
ROBEYNS ET AL., J. AM. CHEM. SOC., vol. 130, no. 6, 2008, pages 1979 - 1984
HORVATH ET AL., TETRAHEDRON LETTERS, vol. 48, 2007, pages 3621 - 3623
GU ET AL., NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 24, no. 5-7, 2005, pages 993 - 998
NAUWELAERTS ET AL., NUCLEIC ACIDS RESEARCH, vol. 33, no. 8, 2005, pages 2452 - 2463
ROBEYNS ET AL., ACTA CRYSTALLOGRAPHICA, SECTION F: STRUCTURAL BIOLOGY AND CRYSTALLIZATION COMMUNICATIONS, vol. F61, no. 6, 2005, pages 585 - 586
GU ET AL., TETRAHEDRON, vol. 60, no. 9, 2004, pages 2111 - 2123
GU ET AL., OLIGONUCLEOTIDES, vol. 13, no. 6, 2003, pages 479 - 489
WANG ET AL., J. ORG. CHEM., vol. 68, 2003, pages 4499 - 4505
VERBEURE ET AL., NUCLEIC ACIDS RESEARCH, vol. 29, no. 24, 2001, pages 4941 - 4947
WANG ET AL., J. ORG. CHEM., vol. 66, 2001, pages 8478 - 82
WANG ET AL., NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 20, no. 4-7, 2001, pages 785 - 788
WANG ET AL., J. AM. CHEM., vol. 122, 2000, pages 8595 - 8602
MANOHARAN ET AL., BIOORG. MED. CHEM. LET., vol. 3, 1993, pages 2765 - 2770
LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6553 - 6556
MANOHARAN ET AL., BIOORG. MED. CHEM. LET., vol. 4, 1994, pages 1053 - 1060
MANOHARAN ET AL., ANN. N.Y. ACAD. SCI., vol. 660, 1992, pages 306 - 309
OBERHAUSER ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 533 - 538
SAISON-BEHMOARAS ET AL., EMBO J., vol. 10, 1991, pages 1111 - 1118
KABANOV ET AL., FEBS LETT., vol. 259, 1990, pages 327 - 330
SVINARCHUK ET AL., BIOCHIMIE, vol. 75, 1993, pages 49 - 54
MANOHARAN ET AL., TETRAHEDRON LETT., vol. 36, 1995, pages 3651 - 3654
SHEA ET AL., NUCL. ACIDS RES., vol. 18, 1990, pages 3777 - 3783
MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, vol. 14, 1995, pages 969 - 973
MISHRA ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1264, 1995, pages 229 - 237
CROOKE ET AL., J. PHARMACOL. EXP. THER., vol. 277, 1996, pages 923 - 937
JHA P ET AL., MOL IMMUNOL, vol. 44, no. 16, 2007, pages 3901 - 3908
PATEL, N. ET AL., EYE, vol. 22, no. 6, 2008, pages 768 - 76
ROHRER, B ET AL., INVEST OPHTHALMOL VIS SCI, vol. 50, no. 7, 2009, pages 3056 - 64
BORA, NS ET AL., J IMMUNOL., vol. 177, no. 3, 2006, pages 1872 - 8
SAVIGE ET AL., J AM SOC NEPHROL, vol. 22, no. 8, 2011, pages 1403 - 15
RICHARDS A ET AL., ADV IMMUNOL, vol. 96, 2007, pages 141 - 77
NITSCH, D ET AL., OPHTHALMIC EPIDEMIOL, vol. 16, no. 3, 2009, pages 181 - 6
CHOI, J ET AL., OPHTHALMIC EPIDEMIOL, vol. 18, no. 6, 2011, pages 259 - 63
CRUZSMITH, GENEREVIEWS, 20 July 2007 (2007-07-20)
PICKERING ET AL., NAT GENET, vol. 31, no. 4, 2002, pages 424 - 8
PENNESI ME ET AL., MOL APECTS MED, vol. 33, 2012, pages 487 - 509
LOYET ET AL., INVEST OPHTHALMOL VIS SCI, vol. 53, no. 10, 2012, pages 6628 - 37
THEOFILOPOULOS, A.N.DIXON, F.J., ADVANCES IN IMMUNOLOGY, vol. 37, 1985, pages 269 - 390
ANDREWS, B ET AL., J. EXP. MED., vol. 148, 1978, pages 1198 - 1215
PICKERING, M.C. ET AL., J. EXP. MED., vol. 204, 2007, pages 1249 - 56

Citation (search report)

[I] WO 2004103288 A2 20041202 - NEW YORK SOC FOR THE RUPTURED [US], et al

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2015038939 A2 20150319; WO 2015038939 A3 20150702; AU 2014318580 A1 20160303; AU 2014318580 B2 20191212; AU 2020201763 A1 20200402; BR 112016004671 B1 20201229; CA 2921842 A1 20150319; CL 2016000606 A1 20170217; CL 2018002334 A1 20181214; CN 105744959 A 20160706; CN 105744959 B 20201201; CN 112359042 A 20210212; CR 20160170 A 20160715; DK 3043827 T3 20190826; DO P2016000063 A 20160601; EA 035433 B1 20200615; EA 201690582 A1 20160729; EP 3043827 A2 20160720; EP 3043827 A4 20170524; EP 3043827 B1 20190703; EP 3603677 A1 20200205; ES 2745758 T3 20200303; HK 1225638 A1 20170915; HR P20191600 T1 20191129; HU E045109 T2 20191230; IL 244095 A0 20160421; JP 2016533765 A 20161104; JP 2020036600 A 20200312; JP 2022058784 A 20220412; JP 6666250 B2 20200313; JP 7158363 B2 20221021; JP 7297112 B2 20230623; KR 102381790 B1 20220331; KR 20160054595 A 20160516; LT 3043827 T 20190812; MA 38959 A1 20170831; MX 2016003263 A 20161208; MX 2020001258 A 20200320; MX 371518 B 20200131; MY 181251 A 20201221; PE 20160500 A1 20160521; PE 20190354 A1 20190307; PH 12016500443 A1 20160516; PL 3043827 T3 20200331; PT 3043827 T 20190926; RS 59252 B1 20191031; RU 2016113763 A 20171016; RU 2662967 C2 20180731; SG 10201806787V A 20180927; SG 11201601445X A 20160330; SI 3043827 T1 20190830; UA 119046 C2 20190425; US 11926830 B2 20240312; US 2016222389 A1 20160804; US 2019048351 A1 20190214; US 2020149047 A1 20200514; US 2022243209 A1 20220804; ZA 201601236 B 20170531

DOCDB simple family (application)

US 2014055458 W 20140912; AU 2014318580 A 20140912; AU 2020201763 A 20200311; BR 112016004671 A 20140912; CA 2921842 A 20140912; CL 2016000606 A 20160314; CL 2018002334 A 20180814; CN 201480056788 A 20140912; CN 202011263979 A 20140912; CR 20160170 A 20160412; DK 14844168 T 20140912; DO 2016000063 A 20160311; EA 201690582 A 20140912; EP 14844168 A 20140912; EP 19182415 A 20140912; ES 14844168 T 20140912; HK 16114054 A 20161209; HR P20191600 T 20190904; HU E14844168 A 20140912; IL 24409516 A 20160209; JP 2016542824 A 20140912; JP 2019201990 A 20191107; JP 2022011551 A 20220128; KR 20167009610 A 20140912; LT 14844168 T 20140912; MA 38959 A 20140912; MX 2016003263 A 20140912; MX 2020001258 A 20160311; MY PI2016700852 A 20140912; PE 2016000376 A 20140912; PE 2018003111 A 20140912; PH 12016500443 A 20160308; PL 14844168 T 20140912; PT 14844168 T 20140912; RS P20191160 A 20140912; RU 2016113763 A 20140912; SG 10201806787V A 20140912; SG 11201601445X A 20140912; SI 201431272 T 20140912; UA A201603969 A 20140912; US 201415021651 A 20140912; US 201815912386 A 20180305; US 201916439317 A 20190612; US 202117465035 A 20210902; ZA 201601236 A 20160222